Erlocip 150mg Tablet (Erlotinib)
US$ 205 – US$ 683
Buy Erlotinib 150 mg Online, which is Anti-Cancer medication, and it contains Erlotinib. Erlocip 150 mg are given to patients to treat different forms of cancer. Erlotinib Tablets are chemotherapy drugs and can lower or stop the growth of cancer cells.
Active Ingredient | |
---|---|
Strength | 150mg |
Dosage Form | Tablet |
Manufacturer | |
Packaging | 30 tablets in a bottle |
Delivery Time | 12-18 Working Days |
Description
Buy Erlotinib 150 mg Online, which is an anti-cancer medication used for the treatment of non-small cell lung cancer at an advanced stage. Erlocip 150 mg has an active ingredient Erlotinib which is a tyrosine kinase inhibitor that harms cancer cells, causing their death. Erlotinib 150 mg is prescribed as initial therapy if cancer cells have specific EGFR mutations. Erlotinib Tablets are also prescribed if the disease remains largely unchanged after initial chemotherapy.
How to Use Erlocip 150 mg?
Erlocip 150 mg is for oral consumption, preferably taken on an empty stomach. The suggested daily dose is one tablet taken with a glass of water or as prescribed by the doctor. Do not chew or break the tablet; swallow it as a whole.
Side Effects of Erlotinib 150 mg
Erlotinib 150 mg cause some major and minor side effects. The major ones include diarrhea, rash, burning or tingling sensation, cough, lower back or side pain, chills and fever, hair loss, and loss of appetite. The minor symptoms include blurred vision, convulsions, chest pain, or discomfort.
Substitute
FAQs:
How does Erlocip 150mg work?
It belongs to a class of medications called tyrosine kinase inhibitors. This works by blocking the action of certain proteins called epidermal growth factor receptor (EGFR) tyrosine kinases. EGFR is involved in the growth and spread of cancer cells. By inhibiting EGFR, Erlocip helps to slow down or stop the growth of cancer cells.
Muchas gracias. ?Como puedo iniciar sesion?
My dad was determined to have Non-Small Cell Lung Cancer with EGFR transformation in May 2014 and has done excellently.